|drug2152||Nasopharyngeal swab Wiki||0.22|
|drug899||Convalescent plasma Wiki||0.12|
|D003141||Communicable Diseases NIH||0.04|
There are 3 clinical trials
This study will assess the prevalence and incidence of COVID-19 infection in patients with chronic plaque psoriasis on immunosuppressant therapy.
To determine if there is a need for further education on vaccines with psoriasis patients who are on a biologic. In regards to the COVID-19, it is important that psoriasis patients - whether on a biologic or not - understand whether they can have certain vaccines. That will depend on the type of vaccine that becomes available.
Description: Assessment is based upon survey responses. By answering multiple questions we will determine if more education is needed based on the answers.Measure: Percentage of patients not understanding the interaction of vaccines and their biologic, assessed with voluntary survey. Time: Data will be collected over a span of 3 months
COVID-19 had a major impact on dermatology practice globally with special emphasis on chronic diseases e.g. psoriasis. The main objective of this work is to investigate the effect of COVID-19 pandemic on psoriasis management. This work is designed as a cross-sectional survey based on a questionnaire directed to Egyptian dermatologists.
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports